Midatech Pharma PLC (MTP)
Market Closed
24 Mar, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 29
-0.06
-18.5%
$
1.98M Market Cap
- P/E Ratio
0% Div Yield
164,362 Volume
- Eps
$ 0.35
Previous Close Day Range
0.29 0.35
Year Range
0.19 20.8
Want to track MTP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MTP closed Friday lower at $0.29, a decrease of 18.5% from Thursday's close, completing a monthly increase of or $0.29. Over the past 12 months, MTP stock gained .
MTP is not paying dividends to its shareholders.
Midatech Pharma PLC has completed 4 stock splits, with the recent split occurring on Mar 27, 2023.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
MTP Chart
Midatech Pharma PLC Dividends
MTP is not paying dividends to its shareholders.
Midatech Pharma PLC Earnings
MTP have yet to publish their earning reports.
MTP is not paying dividends to its shareholders.
MTP have yet to publish their earning reports.
Midatech Pharma PLC (MTP) FAQ
What is the stock price today?
The current price is $0.29.
On which exchange is it traded?
Midatech Pharma PLC is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is MTP.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 1.98M.
Has Midatech Pharma PLC ever had a stock split?
Midatech Pharma PLC had 4 splits and the recent split was on Mar 27, 2023.
Midatech Pharma PLC Profile
| Biotechnology Industry | Healthcare Sector | Stephen A. Stamp CEO | NASDAQ (CM) Exchange | 59564R104 Cusip |
| GB Country | 20 Employees | - Last Dividend | 26 Sep 2022 Last Split | - IPO Date |
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Contact Information
Address: 1 Caspian Point
Phone: 44 29 2048 0180
Website: https://www.midatechpharma.com
2025 © Marketlog. All Rights Reserved.
